Semaglutide

Safety of Semaglutide.

Smits MM, et al. · Frontiers in endocrinology · 2021

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Davies M, et al. · Lancet (London, England) · 2021

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery S, et al. · JCI insight · 2020

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

Tan HC, et al. · Journal of the ASEAN Federation of Endocrine Societies · 2022

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Yang XD, et al. · Drug design, development and therapy · 2024

Wegovy (semaglutide): a new weight loss drug for chronic weight management.

Singh G, et al. · Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

Bikou A, et al. · Expert opinion on pharmacotherapy · 2024

Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.

Hathaway JT, et al. · JAMA ophthalmology · 2024

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

Pratley RE, et al. · The lancet. Diabetes & endocrinology · 2018

Semaglutide: First Global Approval.

Dhillon S · Drugs · 2018

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Karagiannis T, et al. · Diabetologia · 2024

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

Kadowaki T, et al. · The lancet. Diabetes & endocrinology · 2022